PMID- 8797712
OWN - NLM
STAT- MEDLINE
DCOM- 19961029
LR  - 20191024
IS  - 1077-9450 (Print)
IS  - 1077-9450 (Linking)
VI  - 13 Suppl 1
DP  - 1996
TI  - HTLV-I-induced T-cell activation.
PG  - S107-13
AB  - Infection by the human T-cell lymphotropic virus type I (HTLV-I) causes T-cell 
      activation by at least two separate mechanisms. One mechanism involves activation 
      of the T cells harboring the virus and is exemplified by in vivo infected 
      nonimmortalized T-cell clones that display a prolonged state of activation. This 
      HTLV-I-induced T-cell activation is inhibited by rapamycin, a drug that inhibits 
      p70 S6-kinase and blocks cell cycle in G1, but is not inhibited by FK506 or 
      cyclosporin A, both of which inhibit interleukin-2 (IL-2) production. The 
      phenotype of this pathway is consistent with an hyperactive IL-2R pathway or CD28 
      pathway, indicating that HTLV-I may contribute a costimulatory signal to the 
      infected T cell. As a separate mechanism, HTLV-I-infected T cells can induce 
      activation of uninfected T cells via T-T-cell interaction mediated by the 
      LFA-3-CD2 pathway. This may induce IL-2 production from the uninfected T cells, 
      leading to a more generalized activation of the immune system that potentially 
      could provide a basis for some of the diseases associated with HTLV-I. Moreover, 
      this THTLV-I-T-cell interaction could explain the spontaneous proliferation 
      observed in patients with HTLV-I-associated myelopathy/tropical spastic 
      paraparesis.
FAU - Buckle, G J
AU  - Buckle GJ
AD  - Laboratory of Molecular Immunology, Brigham and Women's Hospital, Boston, 
      Massachusetts, USA.
FAU - Hafler, D A
AU  - Hafler DA
FAU - Hollsberg, P
AU  - Hollsberg P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - J Acquir Immune Defic Syndr Hum Retrovirol
JT  - Journal of acquired immune deficiency syndromes and human retrovirology : 
      official publication of the International Retrovirology Association
JID - 9501482
RN  - 0 (CD2 Antigens)
RN  - 0 (CD28 Antigens)
RN  - 0 (Cytokines)
RN  - 0 (Gene Products, tax)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Interleukin-2)
RN  - 0 (Polyenes)
RN  - 83HN0GTJ6D (Cyclosporine)
RN  - W36ZG6FT64 (Sirolimus)
RN  - WM0HAQ4WNM (Tacrolimus)
SB  - IM
MH  - CD2 Antigens/drug effects/physiology
MH  - CD28 Antigens/drug effects/physiology
MH  - Cyclosporine/pharmacology
MH  - Cytokines/biosynthesis
MH  - G1 Phase/drug effects
MH  - Gene Products, tax/physiology
MH  - HTLV-I Infections/*immunology
MH  - Human T-lymphotropic virus 1/*immunology
MH  - Humans
MH  - Immunosuppressive Agents/pharmacology
MH  - Interleukin-2/biosynthesis
MH  - Lymphocyte Activation/drug effects/*immunology
MH  - Polyenes/pharmacology
MH  - S Phase/drug effects
MH  - Sirolimus
MH  - T-Lymphocytes/*immunology/virology
MH  - Tacrolimus/pharmacology
RF  - 68
EDAT- 1996/01/01 00:00
MHDA- 1996/01/01 00:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 1996/01/01 00:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
AID - 10.1097/00042560-199600001-00018 [doi]
PST - ppublish
SO  - J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S107-13. doi: 
      10.1097/00042560-199600001-00018.